Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine plus target-controlled remifentanil for sedation during ERCP in elderly patients
ChiCTR2200058413Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine, remifentanil and propofol in gastrointestinal conditions (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Oxygen saturation. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
dexmedetomidineremifentanilpropofol
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2200058413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058413.